Market Overview

ScanSource's Q4 Earnings Preview

Share:

ScanSource (NASDAQ: SCSC) announces its next round of earnings this Tuesday, August 20. Here is Benzinga's everything-that-matters guide for the Q4 earnings announcement.

Earnings and Revenue

Wall Street expects EPS of 82 cents and sales around $999.63 million.

In the same quarter last year, ScanSource posted a profit of 77 cents on sales of $993.85 million. The Wall Street estimate would represent a 6.49% increase in the company's earnings. Revenue would be up 0.58% on a year-over-year basis. Here's how the company's reported EPS has stacked up against analyst estimates in the past:

 

Quarter Q3 2019 Q2 2019 Q1 2019 Q4 2018
EPS Estimate 0.800 0.97 0.87 0.77
EPS Actual 0.770 0.99 0.89 0.77

Stock Performance

Over the last 52-week period, shares are down 25.98%. Given that these returns are generally negative, long-term shareholders are probably a little upset going into this earnings release. Analyst estimates are adjusted higher for EPS and revenues over the past 90 days. The average rating by analysts on ScanSource stock is a Neutral. The strength of this rating has maintained conviction over the past 90 days.

Conference Call

ScanSource is scheduled to hold a conference call at 5:00 p.m. ET and it can be accessed here: https://edge.media-server.com/mmc/p/mymrnxnp

Posted-In: Earnings News

 

Related Articles (SCSC)

View Comments and Join the Discussion!
Fastest Market News Application
You'll Hear It First On Pro
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Trading Daily
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com

The Daily Biotech Pulse: FDA Likes Nabriva's Antibiotic, Snubs Sarepta's DMD Drug; Moderna Gets Fast Track Designation For Zika Vaccine

Earnings Preview: Nordson